ArticleBMC cancer2026
Phase I clinical trial of lobaplatin combined with image-guided volume-modulated arc radiation therapy in locally advanced cervical cancer.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundWe aimed to determine the maximum tolerable dose (MTD) and dose-limiting toxicities (DLTs) of weekly lobaplatin chemotherapy concurrent with external beam radiotherapy (EBRT) using image-guided volumetric-modulated arc therapy (VMAT) and brachytherapy in locally advanced cervical cancer (LACC).
methodsPatients with clinical stage IB3-IVA cervical cancer were enrolled following a standard 3 + 3 dose escalation design. Patients received EBRT with 45 Gy in 25 fractions to the pelvis and 60 Gy in 25 fractions to the involved lymph nodes. Then high-dose-rate intracavitary brachytherapy was conducted with 28 Gy in 4 fractions. The starting dose of weekly lobaplatin was 8 mg/m
resultsBetween December 2020 and October 2022, 21 patients were enrolled. Three patients experienced DLTs: grade 3 fatigue at 14 mg/m
conclusionsThe MTD of weekly lobaplatin concurrent with VMAT and brachytherapy for LACC was established as 14 mg/m
trial registrationThis study is registered with chictr.org, ChiCTR2000040113 on 21 November 2020 prior to participant enrollment, and is now complete.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.